Cancer Immunology (CI) (Project-001)

癌症免疫学 (CI)（项目-001）

• 批准号: 8932191
• 负责人: Nina Bhardwaj
• 金额: $ 0.93万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8932191
• 关键词: Adjuvant; Affect; Antigen Presentation; Antigen-Presenting Cells; Award; Biology; Cancer Center Support Grant; Cancer Immunology Science; Cells; Cellular biology; Clinical; Clinical Trials; Cytotoxic T-Lymphocytes; Dendritic Cell Vaccine; Dendritic Cells; Development; Doctor of Philosophy; Environment; Genomics; Goals; Grant; Helper-Inducer T-Lymphocyte; Immune; Immune System Diseases; Immune response; Immune system; Immunologic Monitoring; Immunologist; Immunology; Immunosuppression; Immunotherapy; Inflammatory Response; Institutes; Joints; Journals; Lead; Malignant Neoplasms; Mediating; Outcome; Peer Review; Pre-Clinical Model; Publications; Publishing; Reporting; Research; Research Personnel; Role; T-Lymphocyte; Testing; Tissues; Translating; Tumor Antigens; Tumor Immunity; abstracting; base; cancer immunotherapy; immunogenicity; improved; inhibitor/antagonist; macrophage; member; novel; pre-clinical; programs; tumor; tumor growth; tumor microenvironment; tumor progression

ABSTRACT – CANCER IMMUNOLOGY RESEARCH PROGRAM Program Leaders: Nina Bhardwaj, MD, PhD Miriam Merad, MD, PhD Cancer progression is characterized by gradual dysregulation of the immune system at multiple levels that is considered to directly contribute to unchecked tumor growth. The central theme of the Cancer Immunology (CI) Research Program is to identify mechanisms underlying the suppression of effective anti-tumor immunity that could instruct the development of novel and impactful immunotherapies. Dendritic cells (DCs), potent antigen presenting cells, initiate anti-tumor immune responses, which are subsequently mediated by CD4+ helper cells and cytotoxic T cells. Immunologists have historically focused on characterizing the role of tumor infiltrating T cells (TILs) in restraining tumor growth, but there is emerging evidence that innate immune cells, such as DC and macrophages, are strongly affected by the tumor micro-environment (TME) and major contributors to tumor progression. The CI Research Program has three main scientific objectives. They are to: 1) Characterize mechanisms underlying DC and macrophage immune dysregulation in the tumor micro-environment; 2) Develop preclinical models to reverse innate immune dysfunction and restore immunogenicity to tumor associated antigens, and 3) Translate preclinical discoveries into cancer immunotherapy trials. The CI program has 21 members, and they represent 10 departments and 3 institutes (The Tisch Cancer Institute, Immunology Institute, Icahn Institute for Genomics and Multiscale Biology). As of July 1, 2014, program members were awarded $4,016,010 in NCI and other peer reviewed cancer-related direct support. Members of the CI Program have been increasingly successful in publishing their research in high impact journals. Since 2011, CI program members published 163 reports, of which 14.7% were intra-programmatic and 23.9% inter-programmatic.

摘要 - 癌症免疫学研究计划 计划负责人：医学博士Nina Bhardwaj，博士Miriam Merad，医学博士 癌症进展的特征是免疫系统在多个级别的等级失调，即 被认为直接有助于不受组织的肿瘤生长。癌症免疫学的中心主题 （CI）研究计划是确定抑制有效抗肿瘤免疫力的基础机制 这可以指导新颖和有影响力的免疫疗法的发展。树突状细胞（DC），有效 抗原呈现细胞，启动抗肿瘤免疫调查，随后由CD4+介导 辅助细胞和细胞毒性T细胞。免疫学家历史上一直致力于表征肿瘤的作用 浸润T细胞（TILS）在约束肿瘤生长中，但有新兴的证据表明先天免疫细胞， 例如DC和巨噬细胞，受肿瘤微环境（TME）和主要的强烈影响 肿瘤进展的贡献者。 CI研究计划具有三个主要的科学目标。他们要：1）表征机制 肿瘤微环境中的基础直流和巨噬细胞免疫失调； 2）发展临床前 逆转先天免疫功能障碍并恢复对肿瘤相关抗原的免疫原性的模型，并 3）将临床前发现转化为癌症免疫疗法试验。 CI计划有21名成员，他们代表10个部门和3个机构（Tisch Cancer 伊坎基因组学和多尺度生物学研究所免疫学研究所研究所。截至2014年7月1日， 计划成员在NCI中获得了4,016,010美元的奖励，并获得了其他与癌症相关的直接支持。 CI计划的成员越来越成功地发表其高影响力的研究 期刊。自2011年以来，CI计划成员发表了163份报告，其中14.7％是概括性的 和23.9％的程序间。